Alethia BioTherapeutics
Immunotherapeutics against disease-specific targets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | $4.0m | Debt | |
| Total Funding | 000k | ||
Related Content
Alethia Biotherapeutics is a biotechnology company focused on developing novel therapies for the treatment of invasive carcinomas. The company's core product, AB 16B5, is a humanized IgG2 antibody that targets and inhibits the epithelial to mesenchymal transition (EMT), a process that allows cancer cells to become more invasive and resistant to chemotherapy. By blocking EMT, AB 16B5 has shown in preclinical studies to increase the effectiveness of standard chemotherapy and reduce cancer cell invasion.
Alethia primarily serves the oncology market, targeting patients with advanced carcinomas who require more effective treatment options. The company operates within the biopharmaceutical industry, leveraging cutting-edge research and development to bring innovative cancer therapies to market.
Alethia's business model involves advancing its drug candidates through clinical trials, securing regulatory approvals, and ultimately partnering with larger pharmaceutical companies for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties on product sales.
Keywords: EMT inhibitor, carcinoma, antibody therapy, oncology, chemotherapy enhancement, cancer treatment, biopharmaceutical, clinical trials, FDA approval, innovative therapies.